For research use only. Not for therapeutic Use.
CRX-526(CAT: I025226) is a potent Toll-like receptor 4 (TLR4) antagonist known for its protective effects against advanced diabetic nephropathy. By inhibiting TLR4 signaling, CRX-526 reduces inflammation and oxidative stress, key contributors to the progression of diabetic nephropathy. This mechanism makes it particularly significant in metabolic and renal research, where it is used to explore therapeutic strategies for mitigating chronic inflammation and tissue damage associated with diabetes. Its specificity and efficacy in targeting TLR4 pathways position CRX-526 as a valuable tool for developing treatments for diabetic complications and other inflammation-driven disorders.
Catalog Number | I025226 |
CAS Number | 245515-64-4 |
Synonyms | CRX-526; CRX 526; CRX526; |
Molecular Formula | C69H127N2O19P |
Purity | 98% |
Solubility | Soluble in DMSO |
Appearance | unknown |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | (2S)-2-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-3-[(2R,3R,4R,5S,6R)-3-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-4-[(3R)-3-hexanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid |
InChI | InChI=1S/C69H127N2O19P/c1-7-13-19-22-25-28-31-34-40-43-54(85-61(75)46-37-16-10-4)49-59(73)70-57(68(79)80)53-84-69-65(71-60(74)50-55(86-62(76)47-38-17-11-5)44-41-35-32-29-26-23-20-14-8-2)67(66(58(52-72)88-69)90-91(81,82)83)89-64(78)51-56(87-63(77)48-39-18-12-6)45-42-36-33-30-27-24-21-15-9-3/h54-58,65-67,69,72H,7-53H2,1-6H3,(H,70,73)(H,71,74)(H,79,80)(H2,81,82,83)/t54-,55-,56-,57+,58-,65-,66-,67-,69-/m1/s1 |
InChIKey | PRIXXGNJDNLMBH-DPGPRPECSA-N |
SMILES | O=C(O)[C@@H](NC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O)[C@H]1NC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O |